The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase III study of single-dose casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting.
P. J. Hesketh
Consultant or Advisory Role - GlaxoSmithKline
V. Moiseyenko
No relevant relationships to disclose
G. Rosati
No relevant relationships to disclose
A. Makhson
Honoraria - Amgen; AstraZeneca; Lilly
J. Levin
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
M. W. Russo
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline